Latest Breaking News On - Ligand conjugate - Page 4 : comparemela.com

(0) - Coave Therapeutics is the new name for Horama and reflects its new emphasis on AAV-Ligand Conjugate based vectors for CNS diseases alongside Ocular diseases - Funding led by Seroba Life Sciences and supported by Théa Open Innovation, eureKARE and existing shareholders PARIS, July 21, 2021 /PRNewswire/ Coave Therapeutics (pronounced cove ; formerly Horama), a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, announces a €21.2 million ($25.1 million) expansion of its Series B funding round, bringing the total raised to €33.1 million ($39 million). This financing was led by Seroba Life Sciences, supported by new investors Théa Open Innovation and eureKARE alongside existing shareholders Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital, and Sham Innovation Santé/Turenne.

Clermont ferrandUnited statesFrance generalFranche comtérIrkutskaya oblastAlexandre mouradianSylvie berrebiBruno montanariPartner at seroba life sciencesSeroba life sciencesLigand conjugateOpen innovationCentral nervous systemOmnes capitalV bio venturesKurma partners